Ocular Toxicity Appears Common With Belantamab Mafodotin in Advanced Multiple Myeloma

by | Jul 21, 2022 | Myeloma News | 0 comments

Source: Myeloma – Hematology Advisor

Researchers sought to determine whether ocular toxicity occurred in a significant number of patients with multiple myeloma treated with belantamab mafodotin.
Read More

Submit a Comment